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Abstract
Background/Aim. It is known that bile acids improve the
absorption, bioavailability and pharmacodynamic characteris-
tics of some drugs. Morphine analgesia is produced by acti-
vation of opioid receptors within the central nervous system
(CNS) at both spinal and supraspinal levels. Since a morphine
molecule contains 3 polar groups and therefore hard to trans-
fer through the blood-brain barrier, the aim of the study was
to examine the potential influence of bile acids derivates,
namely sodium salt of monoketocholic acid (MKH-Na) and
methyl ester of monoketocholic acid (MKH-Me), on analge-
sic effect of morphine. Methods. White male mice of
NMRI-Haan strain, with body weight of 20–24 g, were used
in this study. The analgesic effect of morphine (administered
by subcutaneous and intramuscular route in a dose of 2
mg/kg), with and without pretreatment with MKH-Na (4
mg/kg) and MKH-Me (4 mg/kg) was estimated by the hot
plate method. Results. Administration of MKH-Me prior to
subcutaneous administration of morphine increased the mor-
phine analgesic effect but the increase was not statistically
significant. At the same time administration of MKH-Na did
not affect morphine analgesic effect. The analgesic effect of
morphine increased when administered intramuscularly 20
min after MKH-Me administration. When compared with the
group of animals treated only with morphine, a statistically
significant increase in analgesic effect was detected 10, 30, 40
and 50 min after morphine administration (p < 0.05). Pre-
treatment with MKH-Na did not affect morphine analgesic
effect. Conclusion. According to the results of this study it
can be presumed that after intramuscular morphine admini-
stration methyl ester of monoketocholic acid increases mor-
phine transport into the central nervous system and conse-
quently the analgesic effect, as well. Further research on bile
acids-morphine interaction both in vitro and in vivo is necessary
to completely elucidate the mechanism of this interaction and
increase in the morphine analgesic effect.
Key words:
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Apstrakt
Uvod/Cilj. Poznato je da žuÿne kiseline poboljšavaju ap-
sorpciju, poveýavaju biološku raspoloživost i poboljšavaju
farmakodinamske osobine nekih lekova. Buduýi da je anal-
gezija izazvana morfinom posledica aktivacije opioidnih re-
ceptora u centralnom nervnom sistemu na spinalnom i sup-
raspinalnom nivou, i da molekul morfina sadrži tri polarne
grupe zbog ÿega teško prolazi kroz hematoencefalnu barije-
ru, cilj studije bio je da se ispita potencijalni uticaj derivata
žuÿnih kiselina, natrijumove soli monoketoholne kiseline
(MKH-Na) i metil estra monoketoholne kiseline (MKH-
Me), na analgetski efekat morfina. Metode. Studija je spro-
vedena na belim miševima NMRI-Haan soja, muškog pola,
telesne mase 20–24 g. Analgetski efekat morfina (primenje-
nog supkutano i intramuskularno u dozi 2 mg/kg) sa i bez
pretretmana MKH-Na (4 mg/kg) i MKH-Me (4 mg/kg)
procenjivan je metodom vrele ploÿe.  Rezultati. Primena
MKH-Me pre supkutane primene morfina pojaÿala je anal-
getski efekat morfina bez statistiÿki znaÿajne razlike. Prime-
na MKH-Na nije uticala na analgetski efekat morfina pri-
menjenog supkutano. Analgetski efekat intramuskularno
primenjenog morfina, 20 minuta nakon primene MKH-
Me, bio je pojaÿan. U poreĀenju sa grupom životinja kod
kojih je primenjen samo morfin, statistiÿki znaÿajna razlika
u analgetskom efektu zabeležena je 10, 30, 40 i 50 minuta
nakon njegove  primene (p < 0,05). Pretretman sa MKH-
Na nije uticao na analgetski efekat morfina primenjenog
intramuskularno.  Zakljuÿak. Na osnovu rezulata studije
može se pretpostaviti da nakon intramuskularne primene
morfina metil estar monoketoholne kiseline poveýava
transport morfina u centralni nervni sistem i poslediÿno
dovodi do pojaÿanja analgetskog efekta morfina. Dalja is-
traživanja interakcija žuÿnih kiselina i morfina in vitro i in
vivo neophodna su da bi se u potpunosti rasvetlio mehani-
zam interakcije, a time i mehanizam pojaÿanja analgetskog
efekta morfina.
Kljuÿne reÿi:
morfin; miševi; žuÿne kiseline i soli; krvno-moždana
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Introduction
The application of bile acids in human medicine dates
back to the thirties of the 20th century. It has been shown
that bile acids improve the absorption, bioavailability and
pharmacodynamic characteristics of some drugs 
1, 2. Bile
salts form micelles, which increase the permeability of the
mucosal membrane by overcoming resistance at the aqueous
diffusion layer 
3. They are also capable of enhancing drug
delivery by interacting with membrane lipids and proteins
that affect membrane fluidity 
4. The effects of bile acids on
biological membranes are similar to those of detergents and
they appear to have the potential to aid intestinal, buccal,
transdermal, ocular, rectal and pulmonary absorption 
1.
Morphine is the prototypical opioid analgesic. It interacts
with  and ț opioid receptors to exert its analgesic effect 
5.
Analgesia is produced by activation of opioid receptors within
the central nervous system (CNS) at both spinal and supraspi-
nal levels 
6. Morphine is a weak base that is relatively water
soluble and poorly lipid soluble. After oral administration it is
predominantly absorbed in the proximal small bowel and has a
poor and variable bioavailability (20–40%) 
7. In humans, fol-
lowing absorption, 90% of drug is metabolized, principally by
glucuronidation in the liver, to form morphine-3-glucuronide
(M3G) and morphine-6-glucuronide (M6G). Morphine is
widely distributed within the body. Excretion of morphine oc-
curs predominantly in urine in the form of morphine glucuro-
nides with unchanged morphine representing between 2% and
10% of the total, independently of the dose. Some 70–80% of
an administered dose is excreted within 48 h of administration
and most of this appears within the first 24 h 
8.
Since morphine analgesia is produced by activation of
opioid receptors within the CNS at both spinal and supraspi-
nal levels, the concentration of morphine at any point in time
at active sites in the CNS will depend on the systematic and
the CNS disposition of the drug. Alteration at either of these
locations may influence morphine CNS concentrations and
thus the degree of antinociception.
Having in mind characteristics of bile acids and their
derivates as well as the characteristics of morphine, the aim
of this research was to determine the influence of bile acids
derivates, namely sodium salt of monoketocholic acid
(MKH-Na) and methyl ester of monoketocholic acid (MKH-
Me), on analgesic effect of morphine detected by antinoci-
ceptive hot plate method.
Methods
White male mice of NMRI-Haan strain, with body
weight of 20–24 g, were used in this study. Each control and
experimental group was formed of 6 animals. Animals had
free access to food and water, and subjected to 12-h light and
dark cycles, at a room temperature of 22°C. Laboratory ani-
mals were under human care in accordance with the criteria
given in the ‘Guide for the Care and Use of Laboratory Ani-
mals’ 
9. The study was approved by the Ethics Committee on
Laboratory Animal Welfare of the University of Novi Sad,
approval No. IV-2011-05.
For the experiment we used: morphine from Sigma-
Aldrich; MKH-Na and MKH-Me – synthesized at the De-
partment of Chemistry, Faculty of Sciences, University of
Novi Sad, according to the procedure by Miljkovic et al. 
10;
hot/cold plate – Ugo Basile (kept at 53 ± 1°C); chronometer.
The study groups included the following: C1 – the con-
trol group without treatment (n = 6); C2 – the control group
given morphine intramuscularly (im) at 2.0 mg/kg (n = 6);
C3 – the control group given morphine subcutaneously (sc)
at 2.0 mg/kg (n = 6); C4 – the control group given MKH-Na
subcutaneously (sc) at 4.0 mg/kg (n = 6); C5 – the control
group given MKH-Me subcutaneously (sc) at 4.0 mg/kg (n =
6); E1 – the experimental group given MKH-Na sc 4.0
mg/kg 20 min before morphine im at 2.0 mg/kg (n = 6); E2 –
the experimental group given MKH-Me sc 4.0 mg/kg 20 min
before morphine im at 2.0 mg/kg (n = 6); E3 – the experi-
mental group given MKH-Na sc 4.0 mg/kg 20 min before
morphine  sc at 2.0 mg/kg (n = 6); E4– the experimental
group given MKH-Me sc 4.0 mg/kg 20 min before morphine
sc at 2.0 mg/kg (n = 6).
The doses and time interval of administration of bile
acid derivates were determined according to previously pub-
lished studies in which they were determined to be optimal
for the analgesic model used in this study 
11–13.
The analgesic effect of morphine was estimated by the
hot plate method 
14. Mice were gently restrained and placed on
the hot plate surface (53 ± 1°C). The latency for paw with-
drawal from the heated surface was manually recorded with a
chronometer. Only the clear withdrawal of the either rear paw
was taken into account, discarding the nonspeci¿c generalized
struggle observed in some cases. Three measures at 10-min
intervals were taken at the beginning of the study or before the
treatment (groups of animals other than the control one) and
their means were considered as basal (control) latencies. The
mean basal values were sought around 11–13 s and animals
showing any latency equal to or higher than 20 s were rejected.
A maximal latency value (cut-off) of 30 s was determined.
The latency for paw withdrawal from the heated sur-
face (reaction time in seconds) was recorded as follows:
control (basal) reaction time for each animal in all the study
groups; the study group C1 – experimental reaction time
was recorded at 10, 20, 30, 40, 50, 60, 80, 100 and 120 min
after CRT measurement; study groups C2, C3, E1, E2, E3
and E4 – ERT was recorded 10, 20, 30, 40, 50, 60, 80, 100
and 120  min after morphine administration; study groups
C4 and C5 – reaction time measurement started 20 min af-
ter MKH-Na and MKH-Me administration (control reaction
time). The experimental reaction time was recorded at 10,
20, 30, 40, 50, 60, 80, 100 and 120 min from this time
point.
The morphine dose for both routes of administration
was 2.0 mg/kg. The analgesic effect determined in seconds
was expressed as a percentage of prolongation of measured
experimental reaction time (ERT) compared to control reac-
tion time (CRT) according to the equataion:
Analgesic effect (%) = (ERT – CRT)
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Statistical analysis of collected data was performed by
MedCalc 9.2.0.1. The statistical significance was determined
using Student’s t-test. A p-value of 0.05 was considered sta-
tistically significant.
Results
Figure 1 shows that MKH-Me administration prior to
subcutaneous administration of morphine increased the mor-
phine analgesic effect, but this increase was not statistically
significant. At the same time MKH-Na administration did
not affect morphine analgesic effect.
Figure 2 shows the increased analgesic effect of mor-
phine when morphine was administered intramuscularly 20
min after MKH-Me administration. When compared with the
group of animals treated only with morphine, a statistically
significant increase in analgesic effect was detected 10, 30,
40 and 50 minutes after morphine administration (p < 0.05).
Pretreatment with MKH-Na did not affected morphine anal-
gesic effect after its intramuscular administration.
Discussion
Since it is known that morphine molecule containing 3
polar groups hardly passes through the blood-brain barrier
(BBB), the potential influence of bile acids derivates on
blood-brain barrier permeability and the influence on analge-
sic effect of morphine was examined.
In this experiment hidrosoluble sodium salt of
monoketocholic acid did not affect morphine analgesic effect
regardless the route of morphine administration. Similar
findings were obtained in the study of Vasovic et al. 
13, in
which no significant interaction of sodium salt of monoketo-
cholic acid and tramadol was detected regarding the antino-
ciceptive effect in healthy mice.
This finding is in accordance with some authors sug-
gesting that liposoluble derivates of bile acids are more suc-
cessful in promoting drug transport through biological barri-
ers 
1, 15. The results published by Posa et al. 
12, 16, who studied
lidocaine and bile acid derivates interactions, also support
this assertion. However the potential of hidrosoluble salts of
bile acids to promote drug transport was also verified 
11, 17, 18.
In our study methlyester of monoketocholic acid (lipo-
soluble), given subcutaneously 20 minutes before subcutane-
ous morphine administration, enhanced morphine analgesic
effect although the increase in analgesic effect was not sta-
tistically significant when compared to experimental group
treated only with morphine. On the other hand methylester
statistically significantly increased the analgesic effect of
morphine when morphine was administered intramuscularly.
This increase in analgesic effect in the period from 10 to 50
min after morphine administration was statistically signifi-
cant compared to animals treated only with morphine except
at the time point of 20 min after morphine administration.
According to Kuhajda et al. 
19, this could be attributed to
the formation of two different types of the molecular aggre-
gates between bile acids and morphine. Molecular aggregate
of morphine and one molecule of 12-monoketocholic acid (12-
MKC) in which morphine binds to the side of the steroid
skeleton of 12-MKC, results in a molecular aggregate that is
more hydrophobic than the morphine itself what accelerates
the ingression of morphine to the lipid phase of the membrane
and increases its analgesic effect. The additional increase in
analgesic effect results from the formation of the hydrophilic
aggregate of the two bile acid molecules with one molecule of
morphine in the intracellular space. Since hydrophilic aggre-
gate is less lipophilic than morphine itself the morphine flux
directed towards the extracellular space is reduced.
Another possible mechanism to which the increase in
analgesic effect could be attributed is the inhibition of P-
glycoprotein (P-gp) mediated morphine efflux from the CNS.
P-gp, located in brain capillary endothelial cell membranes,
may function as a component of the blood-brain barrier 
20, 21.
Fig. 1 – Analgesic effect after subcutaneous administration of
morphine, morphine + sodium salt of monoketocholic acid
(MKH-Na) and morphine + methyl ester of monoketocholic
acid (MKH-Me) before morphine administration and 10, 20,
30, 40, 50, 60, 80, 100 and 120 minutes after morphine admi-
nistration for the groups C3, E3, E4 and  at the correspon-
ding time points for the groups C1, C4 and C5.
Fig. 2 – Analgesic effect after intramuscular administration
of morphine, morphine + sodium salt of monoketocholic acid
(MKH-Na) and morphine + methyl ester of monoketocholic
acid (MKH-Me) before morphine administration and 10, 20,
30, 40, 50, 60, 80, 100 and 120 min after morphine adminis-
tration for the groups C2, E1, E2 and  at the corresponding
time points for the groups C1, C4 and C5. (*p < 0.05).Strana 770 VOJNOSANITETSKI PREGLED Volumen 71, Broj 8
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Morphine may be a substrate for a P-gp, as demonstrated in
vitro and in knockout mice studies 
22, 23. Disruption of P-gp
in brain capillary endothelial cells would in theory result in
enhanced accumulation of morphine in the brain. Since it is
known that bile acids are also substrates for the P-gp the pos-
sible mechanism could involve competition for the P-gp
transport system between bile acids and morphine 
24, 25.
One fact in this study remains to be further studied.
Although the increase in analgesic effect was detected after
subcutaneous administration of methyl ester of monoketo-
cholic acid it was not statistically significant. At the same
time a detected increase in analgesic effect was statistically
significant after intramuscular administration of methyl ester
of monoketocholic acid. Whether this occurred due to higher
standard deviation of the measured values in the experimen-
tal group treated subcutaneously or there exist some differ-
ences in pharmacokinetics related to different routes of ad-
ministration, it remains to be further studied. According to
most of the studies there is no significant difference in ab-
sorption of morphine after intramuscular and subcutaneous
administration 
26, 27. However some studies suggest there ex-
ists a difference in plasma levels 15 min after administration,
with higher levels detected after subcutaneous administra-
tion. It is possible that due to intense liver metabolism better
part of subcutaneously administered dose of morphine is
metabolised to morphine-6-glucuronide which posses a
weaker analgesic effect than morphine 
28, 29, or morphine-3-
glucuronide which is without analgesic effect at all 
30, 31, and
even has the potential of antagonising morphine analgesic ef-
fect 
32, 33. In that manner smaller amount of morphine would
be available for possible interaction with bile acids at the
level of blood-brain barrier. Consequently lower amount of
morphine would be present in CNS resulting in weaker anal-
gesic effect. On the other hand, some sources state that the
peak analgesia of morphine occurs within 50–90 min fol-
lowing subcutaneous administration and 30–60 min after in-
tramuscular injection without explaining what is the back-
ground of this difference 
34. If this is maybe a consequence
of slower or weaker absorption of morphine after subcutane-
ous administration remains to be further studied.
Conclusion
According to the results of this study it can be pre-
sumed that after intramuscular morphine administration
methyl ester of monoketocholic acid increases morphine
transport into the central nervous system and the analgesic
effect, as well. Further research on bile acids-morphine inter-
action both in vitro and in vivo is necessary to completely
elucidate the mechanism of this interaction and increase in
the morphine analgesic effect.
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